Brian Heineman, DO
Adolescent Medicine · Grinnell, IANPI 1548341035
Payments from drug & device makers
Across 364 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Amgen$822
- Pfizer$490
- Lilly USA, LLC$424
- Boehringer Ingelheim$361
- AbbVie$331
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,51296%
- Education$2134%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 52 | $1,064 |
| Amgen | 53 | $822 |
| Pfizer | 37 | $490 |
| Lilly USA, LLC | 30 | $424 |
| Boehringer Ingelheim | 24 | $361 |
| AbbVie(2 entities) | 19 | $331 |
| Novo Nordisk | 16 | $254 |
| Johnson & Johnson | 17 | $249 |
| Novartis | 15 | $245 |
| AstraZeneca | 17 | $223 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $127 |
| GSK | 6 | $94 |
| Harmony Biosciences LLC | 5 | $93 |
| Mylan Specialty L.p. | 7 | $92 |
| Exact Sciences | 6 | $88 |
| Kowa Pharmaceuticals America, Inc. | 6 | $84 |
| Bayer | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $56 |
| Regeneron Healthcare Solutions, Inc. | 4 | $52 |
| Esperion Therapeutics, Inc. | 4 | $50 |
| Seqirus USA Inc | 3 | $45 |
| Genentech USA, Inc. | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Alkermes, Inc. | 1 | $29 |
| Almatica Pharma LLC | 2 | $26 |
| Dexcom, Inc. | 1 | $26 |
| Avanir Pharmaceuticals, Inc. | 2 | $23 |
| Eisai Inc. | 2 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Viatris Specialty LLC | 1 | $15 |
| Merck | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$125
How this compares
Too few adolescent medicine providers in Iowato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 269 | $100,392 |
| XareltoRivaroxaban | 148 | $60,044 |
| JardianceEmpagliflozin | 114 | $52,123 |
| Invega SustennaPaliperidone Palmitate | 11 | $41,531 |
| OzempicSemaglutide | 21 | $22,490 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $22,057 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $21,091 |
| CreonLipase/Protease/Amylase | 18 | $19,923 |
| Potassium Chloride | 494 | $15,656 |
| FarxigaDapagliflozin Propanediol | 39 | $13,499 |
| TrulicityDulaglutide | 12 | $11,200 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 47 | $9,945 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 30 | $9,495 |
| Fentanyl | 95 | $9,116 |
| MyrbetriqMirabegron | 38 | $8,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invega Sustenna | $249 | $101,575159 claims |
| PfizerEliquis | $490 | $100,392269 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $361 | $58,781127 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $254 | $29,62535 claims |
| AbbVieCreon | $331 | $19,92318 claims |
| GSKShingrix, Arexvy | $94 | $19,44077 claims |
| MerckJanumet, Januvia | $12 | $14,69846 claims |
| AstraZenecaFarxiga | $223 | $13,49939 claims |
| Lilly USA, LLCTrulicity | $424 | $11,20012 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $8,42538 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $4,415368 claims |
| Almatica Pharma LLCSertraline Hcl | $26 | $2,413196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adolescent medicine providers in Iowaon file to place this against a meaningful peer group, so we don't.
Other adolescent medicine in Grinnell
- Michael BrooksDes Moines$408
- Ann RehanSioux City$272
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.